Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Amicus Therapeutics, Inc.

$14.49

0 (0%)

C 45Pipeline Score Overvalued Pharma · Commercial
Market Cap
4.55 B
EPS
-0.09
P/E Ratio
-
Value Trade
76.60 M
SEC Financials
Q4 2025

  • Dilution Risk

    5%

  • Revenue

    185.21 M

  • R&D Expenses

    23.74 M

  • Operating CF

    8.29 M

  • Total Assets

    949.87 M

  • Total Liabilities

    675.63 M

  • Equity

    274.24 M

  • D/E Ratio

    12,345

0.21 %
Week
0.56 %
1 Month
1.54 %
3 Month
70.07 %
6 Month
45.48 %
5 Year
-9.44 %
All Time
Cash Data
Profitable

  • Cash Position

    293.54 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    Feb 20, 2026
Overview
Volume
5.29 M
52 Week Range
5.51 - 14.50
% held by Insiders
1.49 %
% held by Institutions
102.11 %
Enterprise Value
4.70 B
Total Shares
313.93 M
Short %
7.53 %
Float Shares
291.02 M
Company Description
HQ: 47 HULFISH STREET, PRINCETON, ...
Employees:511
https://www.amicusrx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-12-31
DMX-200
phase 3 data readout
Phase 3
—
–
–
–
2025-12-31
DMX-200
phase 3 data readout
Phase 3
—
–
–
–
2025-12-31
DMX-200
phase 3 data readout
Phase 3
—
–
–
–
Unlock 4 more historical catalysts
Drug Pipeline Intelligence
C45
Pipeline Score
$739M
Pipeline Value
Overvalued
Valuation Signal
11
Drugs Scored
0.5x
rNPV / MCap
Top 70%
Small Cap
(rank 275 of 913)
Percentile Rank
Amicus Therapeutics, Inc. carries a moderate pipeline score (45/100), with $1.1B risk-adjusted pipeline value, led by Afegostat in Gaucher Disease, Type 1 (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
afegostat
Small molecule		Gaucher DiseasePhase 2NCT0081386523% $306M COMPLETED 27 - -May 1, 2012 -Aug 15, 2018
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Pombiliti + Opfolda
late-onset Pompe disease
—
2025-09-08

patients experienced TEAEs: 41; cipa mig discontinuations: 4; serious TEAEs: 2; unrelated TEAEs: 1

Read More

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Read More
Pombiliti + Opfolda
late-onset Pompe disease
—
2025-09-08

patients experienced TEAEs: 41; cipa mig discontinuations: 4; serious TEAEs: 2; unrelated TEAEs: 1

Read More

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Read More
Pombiliti + Opfolda
late-onset Pompe disease
—
2025-09-08

patients experienced TEAEs: 41; cipa mig discontinuations: 4; serious TEAEs: 2; unrelated TEAEs: 1

Read More

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in FOLD
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
FOLD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How FOLD ranks across every disease it competes in
Competitive Position is a premium feature
See how FOLD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial